Cisplatin was found to sensitize mouse glioblastoma tumors to MSC-delivered TRAIL in vitro and in vivo [198], suggesting that combinatorial therapies may effectively sensitize cancer cells to stem cell-delivered TRAIL. This evidence concerns the gene TNFSF10 and glioblastoma.